Active Biotech Interim Report Q2 2024

SECOND QUARTER IN BRIEF

  • Start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3)
  • Active Biotech acquired exclusive rights to patents of tasquinimod in combination therapy in multiple myeloma (May 22)
  • Clinical activity and safety of naptumomab and docetaxel in non-small cell lung cancer were presented at ASCO 2024 (May 28)

EVENTS AFTER THE END OF THE PERIOD

  • Active Biotech entered agreement for a clinical study of tasquinimod in myelofibrosis (July 1)
  • Active Biotech provided an update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma (July 15)

FINANCIAL SUMMARY

SEK M Apr-Jun Jan-Jun Full-year
2024 2023 2024 2023 2023
Net sales
Operating profit/loss -10.7 -11.3 -21.4 -23.1 -46.5
Profit/loss after tax -10.6 -11.2 -21.1 -22.7 -45.8
Earnings per share (SEK) -0.03 -0.04 -0.06 -0.09 -0.17
Cash and cash equivalents (at close of period) 13.9 15.7 36.2

The report is also available at www.activebiotech.com